Investor Presentation

September 21, 2026 To, To, The Listing Department, The Listing Department BSE Limited, National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai – 400001 Mumbai – 400051 Scrip code: 544889 Symbol: SYMBIOTEC Sub: Investor Presentation - Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“SEBI Listing Regulations”) Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI Listing Regulations, please find enclosed Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The aforesaid disclosure is also available on the Company’s website at https://www.symbiotec.com/ This is for your Information and Records. Thanking you, For Symbiotec Pharmalab Limited Salil Jain Company Secretary & Compliance Officer Registered Office & Works: Symbiotec Pharmalab Limited (Formerly known as Symbiotec Pharmalab Pvt. Ltd.) 385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222, Email ID : symbiotec@symbiotec.com, Website : www.symbiotec.com CIN: U24232MP2002PLC015293 Symbiotec Pharmalab Limited Q1FY27 Investor Presentation September 2026 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Symbiotic Pharmalab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. IPO & Market Debut : A New Chapter. A Significant Milestone. Details of IPO  Listing of Symbiotec Pharmalab Limited in September 2026  Listing done on BSE & NSE  IPO Price : Rs. 988 per share  Issue Size: Rs. 1,757 Cr • Fresh Issue: Rs. 150 Cr • Offer for Sale: Rs. 1,607 Cr  Objects of the Issue: Proceeds of Rs. 150 crores to repay or prepayment in full or part of borrowings availed by our Company Symbiotec Pharmalab Limited listed on BSE & NSE on 1st September 2026 Q1FY27 Performance Highlights Q1FY27 Key Business Updates APIs Products Complex Injectables Biotech - CDMO Services  Sales growth steady at 6% in Q1  Licensing agreement for  Industrial Biotech : distribution of two DCV products Growth further expected to Customers on-boarded o in US o pick up in subsequent quarters 10 years take-or-pay agreement Term-sheet signed, Agreement o  Successfully completed 4 major with US based Alternate Protein at advanced stage, expected to regulatory audits recently: player in place sign off shortly EUGMP audits in Rau and 10 years take-or-pay term-sheet o  Successfully filed first molecule o Pithampur plants in Mar 2026 with Europe based Alternate ANDA for DCV in September Protein player in place,  Approval certification 2026 agreement in advanced stage received for both plants First generic filing for the DCV  Bio-Pharmaceutical : Insulin Drug product in US market USFDA audit in Mar-Apr 2026 o Substance (DS) at Rau plant – EIR received  Filing of second ANDA scheduled 5 year Take or Pay agreement in for Q4 FY27 o USFDA audit in Aug 2026 at o place, Capex on track ; filing Pithampur plant – EIR awaited regulatory approval in Q4 FY27 Q1 FY27 Financials Highlights Steady API growth offset by expenses from non-revenue generating New Bizs Consol Revenue (Rs. in Crs) Consol EBITDA (Rs. in Crs) Consol PAT (Rs. in Crs) • Drag of expenses from new businesses not yet generating 29% 21% 15% 6% revenues 218.2 58.0 29.9 - Opex - Rs. 23 crs 203.2 - Depreciation - Rs. 12 crs 45.2 • Revenue generation from 14.1 various new businesses to commence in next 6-12 months Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 API Revenue (Rs. in Crs) API EBITDA (Rs. in Crs) API Profitability Maintained +6% 30% 31%  API Gross margins upwards of 60% across 215.3 +9% 203.2 all quarters 65.8 60.1  API EBIDTA margins steady at ~30% driven by revenue growth and favourable sales mix Q1FY26 Q1FY27 Q1FY26 Q1FY27 Margins ₹ 1,000+ Crs capex invested in New Businesses Revenue to commence in the next 6–12 months ₹ 1,475 Crs ₹ 1,666 Crs 39% Share of Gross Capex in Gross Capex Total Gross Capex Share of Total Gross Capex New Projects yet to (as on 30th June 2026) (est end FY27) currently generating revenue Generate Revenues Gross Capex Total Gross Capex Share of Total Project / Product Commercial Status Remarks (as on 30th Jun 2026) (est by end of FY27) Gross Capex Existing Business API : Catering to existing API revenues 644 644 39% Asset Turns ~1.5X Steroids & Hormones Capex invested over years, and revenue generation in near future ~1,000 Crs or 60% of capex Complex Injectables : Majority of capacity reserved with 356 376 Dual Chamber Vials strategic partner to start generating revenue in 6–12 months CDMO Services Take or pay customer arrangements 471 584 61% (400 kl + 14kl) for majority of capacities Revenue for majority of In discussions with distributors & New API Capex 4 63 new capacities alreadycontracted global players Grand Total 1,475 1,666 100% NEW CDMO CAPEX Q1 FY27 INVESTMENT 600 kl capacities to be initiated backed by customer agreement Gross capex invested ~₹68 Cr Management Commentary Commenting on Q1FY27 performance, Mr. Anil Satwani, Chairman & Managing Director of Symbiotec Pharmalab Limited, said: "Our first results as a listed company reflect a business with a steady growing core and two new growth engines for the future. The API business — built over three decades of steroid chemistry dept [Showing first 8,000 characters — download PDF for full document]